1. Home
  2. KW vs NRIX Comparison

KW vs NRIX Comparison

Compare KW & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kennedy-Wilson Holdings Inc.

KW

Kennedy-Wilson Holdings Inc.

HOLD

Current Price

$10.91

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.82

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KW
NRIX
Founded
1977
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
KW
NRIX
Price
$10.91
$15.82
Analyst Decision
Sell
Strong Buy
Analyst Count
1
12
Target Price
$11.00
$30.58
AVG Volume (30 Days)
1.1M
1.0M
Earning Date
05-06-2026
04-10-2026
Dividend Yield
4.42%
N/A
EPS Growth
50.00
N/A
EPS
N/A
N/A
Revenue
$62,633,000.00
$76,987,000.00
Revenue This Year
$81.79
N/A
Revenue Next Year
N/A
$26.32
P/E Ratio
N/A
N/A
Revenue Growth
23.94
99.31
52 Week Low
$5.98
$8.18
52 Week High
$10.99
$22.50

Technical Indicators

Market Signals
Indicator
KW
NRIX
Relative Strength Index (RSI) 58.95 53.92
Support Level $10.82 $14.61
Resistance Level $10.97 $16.47
Average True Range (ATR) 0.05 0.90
MACD -0.03 0.14
Stochastic Oscillator 50.00 63.07

Price Performance

Historical Comparison
KW
NRIX

About KW Kennedy-Wilson Holdings Inc.

Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: